

**22 SEPTEMBER 2023**

**ASX Announcement**

**NOTIFICATION OF DATE OF 2023 ANNUAL GENERAL MEETING**

**MELBOURNE Australia, 22 September 2023:** AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform advises that the Company's Annual General Meeting (AGM) will be held as a hybrid meeting on 22 November 2023 at 11:00am AEDT at Piper Alderman, Level 23, 459 Collins Street, Melbourne VIC 3000, and via Zoom.

Following formalities, AdAlta's CEO and Managing Director, Dr Tim Oldham will provide a business update to Shareholders.

Further to Listing Rules 3.13.1 and 13.3 and the Company Constitution, nominations for elections of directors at the AGM must be received not less than 35 business days before the meeting, being no later than 4 October 2023.

Further details, including Zoom registration details, will be provided in the forthcoming Notice of Meeting.

In order to receive electronic communications, shareholders are encouraged to contact the share registry, Automic Group, via the details below:

- Visit: [www.automicgroup.com.au](http://www.automicgroup.com.au)
- E-mail: [hello@automic.com.au](mailto:hello@automic.com.au)
- Telephone: (Within Australia) 1300 288 664 (Outside Australia) +61 2 9698 5414
- Scan the QR Code below

Authorised for lodgement by:

**Tim Oldham**  
**CEO and Managing Director**  
**September 2023**

**Shareholders: please update your communication preferences**



We encourage shareholders to update their share registry preferences to receive all communications electronically. Doing so helps us communicate with you in a time-efficient manner on important matters, while minimising our mail costs and environmental impact.

Simply [click here](#) or scan the QR code and follow the instructions.

Not a shareholder, but want to keep across our progress? [Click here](#) to subscribe to our updates using the Stay in Touch form.

## Notes to Editors

### About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody enabled protein and cell therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta is extending Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. Preparation for Phase II clinical studies is also underway. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has a collaboration with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (iPET imaging) against Granzyme B, a biomarker of response to immunoncology drugs, a program now in preclinical development.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: <https://adalta.com.au>

### For more information, please contact:

Investors

Tim Oldham, CEO & Managing Director  
Tel: +61 403 446 665  
E: [t.oldham@adalta.com.au](mailto:t.oldham@adalta.com.au)

Media

IR Department  
Tel: +61 411 117 774  
E: [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)